<DOC>
	<DOCNO>NCT02973685</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety hepatic arterial infusion chemotherapy ( HAIC ) compare transarterial chemoembolization ( TACE ) patient large hepatocellular carcinoma stag BCLC A/B .</brief_summary>
	<brief_title>HAIC Versus TACE Large Hepatocellular Carcinoma Staged BCLC A/B .</brief_title>
	<detailed_description>Transarterial chemoembolization ( TACE ) widely use palliative treatment hepatocellular carcinoma ( HCC ) patient . While number study demonstrate poor effect TACE patient large hepatocellular carcinoma stag BCLC A/B especially tumor large 10 cm . Our previous prospective study also reveal similar result large HCC patient treat TACE . Recently , result preliminary pilot study suggest , compare TACE , hepatic arterial infusion chemotherapy ( HAIC ) may improve survival HCC large HCC . Thus , investigator carry prospective randomize control demonstrate superiority HAIC TACE .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Age range 1875 year ; KPS≥70 ; The diagnosis HCC base diagnostic criterion HCC use European Association Study Liver ( EASL ) , simultaneously stag BCLC A BCLC B base Barcelona Clinic Liver Cancer stag system . Patients must least one tumor lesion accurately measure ; Solitary tumor diameter ≥10cm , invade left right lobe ; multiple tumor , diameter large 7cm . Diagnosed unresectable consensus panel liver surgery expert ; Re command treat TAI TACE consensus panel liver MDT ; No past history TACE , TAI , chemotherapy moleculetargeted treatment ; No Cirrhosis cirrhotic status ChildPugh class A No liver protection therapy 2 week enrol , meet follow laboratory parameter : ( ) Platelet count ≥ 75,000/μL ; ( b ) Hemoglobin ≥ 8.5 g/dL ; ( c ) Total bilirubin ≤ 30mmol/L ; ( ) Serum albumin ≥ 32 g/L ; ( e ) ASL AST ≤ 6 x upper limit normal ; ( f ) Serum creatinine ≤ 1.5 x upper limit normal ; ( g ) INR &gt; 2.3 PT/APTT within normal limit ; ( h ) Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 ; Ability understand protocol agree sign write informed consent document . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . Known serious heart disease endure treatment cardiac ventricular arrhythmia require antiarrhythmic therapy Evidence hepatic decompensation include ascites , gastrointestinal bleeding hepatic encephalopathy Known history HIV History organ allograft Known suspect allergy investigational agent agent give association trial . Evidence bleed diathesis . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer , bone fracture Known central nervous system tumor include metastatic brain disease Poor compliance comply course treatment follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatic arterial infusion chemotherapy</keyword>
	<keyword>Transarterial Chemoembolization</keyword>
	<keyword>BCLC A/B</keyword>
</DOC>